At a glance
- Originator Bristol-Myers Squibb
- Class Antithrombotics
- Mechanism of Action Factor Xa inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Thrombosis
Most Recent Events
- 04 Sep 2001 Discontinued-Preclinical for Thrombosis in USA (Unknown route)
- 08 Apr 1999 New profile
- 08 Apr 1999 Preclinical development for Thrombosis in USA (Unknown route)